You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星医药(600196.SH):控股子公司Gland Pharma拟在印度上市
格隆汇 11-01 18:10

格隆汇11月1日丨复星医药(600196.SH)公布,公司于2019年11月1日召开第八届董事会第八次会议(临时会议),批准并拟提请股东大会批准Gland Pharma Limited公开发行股份并在印度国家证券交易所和孟买证券交易所上市交易。

Gland Pharma成立于1978年,总部位于印度海德拉巴,主要从事小分子注射剂仿制药的开发及生产,董事长为LAU Yiukwan Stanley,首席执行官为Srinivas Sadu。Gland Pharma是印度第一家获得美国FDA批准的注射剂药品生产制造企业,并获得全球各大法规市场的GMP认证,其业务收入主要来自于美国和欧洲。截至公告日,公司(通过控股子公司)合计持有Gland Pharma 74%的股权。

截至2018年12月31日,Gland Pharma的总资产约合人民币62.4502亿元,所有者权益约合人民币47.9626亿元,负债总额约合人民币14.4876亿元;2018年度,Gland Pharma实现营业收入约合人民币19.1292亿万元,实现净利润约合人民币2.8325亿元。以上数据为合并口径,含评估增值摊销。

预计于境外上市完成后,Gland Pharma仍为公司控股子公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account